Oruka raises $180M; ORKA-001 Phase 1 shows ~100-day half-life, supports annual dosing

Oruka Therapeutics, Inc.

Private placement gross proceeds ~$180M; issued 10.9M shares at $15.00 and pre-funded warrants for 1.07M shares.
ORKA-001 half-life ~100 days (>3x risankizumab), PK supports potential once-yearly maintenance dosing.
Phase 1 showed complete STAT3 inhibition through 24 weeks; no severe TEAEs; safety consistent with IL-23 class.
EVERLAST-A Phase 2a enrollment ongoing, data expected 2H 2026; EVERLAST-B Phase 2b to start 1H 2026.
Pro forma shares outstanding ~67.1M; cash expected to fund into 2027 after key data readouts.

item 1.01item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.